These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20187244)

  • 21. Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.
    Mirzaei H; Schieler JL; Rochet JC; Regnier F
    Anal Chem; 2006 Apr; 78(7):2422-31. PubMed ID: 16579629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.
    Gerard M; Debyser Z; Desender L; Baert J; Brandt I; Baekelandt V; Engelborghs Y
    J Neurochem; 2008 Jul; 106(1):121-33. PubMed ID: 18346205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.
    Braak H; de Vos RA; Bohl J; Del Tredici K
    Neurosci Lett; 2006 Mar; 396(1):67-72. PubMed ID: 16330147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease.
    Braak H; Sastre M; Del Tredici K
    Acta Neuropathol; 2007 Sep; 114(3):231-41. PubMed ID: 17576580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solid-state NMR reveals structural differences between fibrils of wild-type and disease-related A53T mutant alpha-synuclein.
    Heise H; Celej MS; Becker S; Riedel D; Pelah A; Kumar A; Jovin TM; Baldus M
    J Mol Biol; 2008 Jul; 380(3):444-50. PubMed ID: 18539297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors.
    Kao SY
    Biochem Biophys Res Commun; 2009 Jul; 385(3):434-8. PubMed ID: 19470380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
    Chu Y; Kordower JH
    Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein.
    Jo E; Fuller N; Rand RP; St George-Hyslop P; Fraser PE
    J Mol Biol; 2002 Jan; 315(4):799-807. PubMed ID: 11812148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oligomeric alpha-synuclein and its role in neuronal death.
    Brown DR
    IUBMB Life; 2010 May; 62(5):334-9. PubMed ID: 20209636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neural activity controls the synaptic accumulation of alpha-synuclein.
    Fortin DL; Nemani VM; Voglmaier SM; Anthony MD; Ryan TA; Edwards RH
    J Neurosci; 2005 Nov; 25(47):10913-21. PubMed ID: 16306404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Interaction of Alpha-synuclein with Membranes and its Implication in Parkinson's Disease: A Literature Review.
    Gonzalez-Horta A
    Nat Prod Commun; 2015 Oct; 10(10):1775-8. PubMed ID: 26669123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human α-synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1.
    Lee HJ; Kang SJ; Lee K; Im H
    Biochem Biophys Res Commun; 2011 Sep; 412(4):526-31. PubMed ID: 21798244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.
    Visanji NP; Brotchie JM; Kalia LV; Koprich JB; Tandon A; Watts JC; Lang AE
    Trends Neurosci; 2016 Nov; 39(11):750-762. PubMed ID: 27776749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No evidence for differential methylation of α-synuclein in leukocyte DNA of Parkinson's disease patients.
    Richter J; Appenzeller S; Ammerpohl O; Deuschl G; Paschen S; Brüggemann N; Klein C; Kuhlenbäumer G
    Mov Disord; 2012 Apr; 27(4):590-1. PubMed ID: 22262231
    [No Abstract]   [Full Text] [Related]  

  • 38. A new role for α-synuclein in Parkinson's disease: Alteration of ER-mitochondrial communication.
    Guardia-Laguarta C; Area-Gomez E; Schon EA; Przedborski S
    Mov Disord; 2015 Jul; 30(8):1026-33. PubMed ID: 25952565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ca2+ is a key factor in α-synuclein-induced neurotoxicity.
    Angelova PR; Ludtmann MH; Horrocks MH; Negoda A; Cremades N; Klenerman D; Dobson CM; Wood NW; Pavlov EV; Gandhi S; Abramov AY
    J Cell Sci; 2016 May; 129(9):1792-801. PubMed ID: 26989132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genetics and molecular biology of alpha-synuclein.
    Farrer M
    Handb Clin Neurol; 2008; 89():313-9. PubMed ID: 18631756
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.